Latest article
Lilly’s tirzepatide beats Ozempic in head-to-head kind 2 diabetes trial
Eli Lilly announced that its investigated GIP and GLP-1 inhibitor tirzepatide has demonstrated superiority over Novo Nordisk's Ozempic in a Phase III study.The SURPASS-2...
ADA 2021 | Weight change has largest affect on longevity for individuals with sort...
medwireNews: Losing weight is the most powerful thing people with type 2...
